We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
CBLL Gets FDA Consent for One-of-a-Kind Delirium Monitoring Solution
Read MoreHide Full Article
Key Takeaways
CeriBell gained FDA clearance for its continuous EEG-based delirium monitoring solution.
The system delivers real-time EEG insights to cut clinical variability and aid earlier delirium detection.
Tested on 225 adults, the algorithm builds on prior Breakthrough status and ties to a CMS NTAP bid.
CeriBell Inc. (CBLL - Free Report) recently announced that the FDA has given 510(k) clearance for its latest delirium monitoring solution, making it the one and only FDA-cleared solution for continuous tracking of delirium. This milestone confirms the Ceribell System as an AI-driven brain-monitoring platform, extending its clinical efficacy by giving doctors useful information to detect risk for both seizures and delirium in more critically ill patients.
Delirium is a major unaddressed critical condition, as current screening relies on occasional bedside assessments, depending on personal judgment, which can vary from one clinician to another. CBLL’s FDA-approved Delirium Monitoring Solution continuously monitors brain activity through electroencephalography (EEG) and notifies clinicians when it sees patterns that suggest delirium. Stanford anesthesiology expert Dr. Juliana Barr says that the technology can potentially improve delirium detection rates, allow faster treatment and reduce the cost burden on both families and hospitals due to missed or delayed diagnoses.
Management noted that the FDA clearance enables CBLL to enlarge its footprint in delirium care by offering the first continuous, objective EEG technology to support doctors with early detection of delirium in critically ill patients. Further, the company will soon wrap up its launch plans and will deliver this breakthrough AI-powered neuro-monitoring technology to patients, making EEG a system-wide standard for brain care.
Likely Trend of CBLL Stock Following the News
Shares of CBLL have lost 3.8% since the announcement on Wednesday. Year to date, shares of CeriBell have declined 21.1% against the industry’s 1.1% growth and the S&P 500’s 19.5% rise.
Image Source: Zacks Investment Research
In the long run, the FDA clearance gives CeriBell a competitive advantage as well as supports its long-term mission of making continuous AI-based EEG technology a standard, essential tool in detecting seizure and delirium — a condition that affects up to 31% of ICU patients, 80% of ventilated patients and increases mortality rate by 10%, with longer hospital stays and higher post-ICU dementia risk. CBLL’s ability to deliver continuous AI-driven monitoring in serious neurological conditions reinforces its strategic vision of making EEG a new vital sign.
CBLL currently has a market capitalization of $748.59 million.
More on the Delirium Monitoring Solution
CBLL’s newly cleared point-of-care EEG system addresses key gaps in delirium, seizure and electrographic status epilepticus care by routine EEG-based screening that provides clinicians with real-time neurological insights to support earlier detection, reduce clinical variability and improve bedside decision-making.
CBLL’s delirium algorithm was tested on 225 critically ill adults, showing real-world reliability. The FDA clearance builds on the technology’s earlier Breakthrough Device Designation and the company has also applied for a New Technology Add-on Payment (NTAP) to the Centers for Medicare and Medicaid Services (CMS) to support hospitals with reimbursement benefits.
Studies show that nearly 48% of ICU patients undergoing seizures develop peri-ictal delirium, and 42% of older ICU patients with delirium show epileptiform discharges. Hence, by innovating an advanced seizure and delirium monitoring tool, CBLL enables thorough diagnosis of patient brain health and guides treatments that may improve outcomes.
Some better-ranked stocks from the broader medical space are Phibro Animal Health (PAHC - Free Report) , AtriCure (ATRC - Free Report) and Boston Scientific (BSX - Free Report) .
Phibro Animal Health, sporting a Zacks Rank #1 (Strong Buy) at present, reported third-quarter 2025 adjusted earnings per share (EPS) of 73 cents, which surpassed the Zacks Consensus Estimate by 23.73%. Revenues of $363.9 million beat the Zacks Consensus Estimate by 2.6%. You can see the complete list of today’s Zacks #1 Rank stocks here.
PAHC has an estimated long-term earnings growth rate of 12.8% compared with the industry’s 13.2% rise. The company beat earnings estimates in the trailing four quarters, the average surprise being 20.77%.
AtriCure, currently carrying a Zacks Rank #2 (Buy), reported a third-quarter 2025 adjusted loss per share of 1 cent, narrower than the Zacks Consensus Estimate by 90.91%. Revenues of $134.3 million beat the Zacks Consensus Estimate by 2.09%.
ATRC has an estimated earnings growth rate of 64.2% for 2025 compared with the industry’s 11.5% rise. The company beat earnings estimates in the trailing four quarters, the average surprise being 67.06%.
Boston Scientific, currently carrying a Zacks Rank #2, reported a third-quarter 2025 adjusted EPS of 75 cents, which surpassed the Zacks Consensus Estimate by 5.63%. Revenues of $5.07 billion beat the Zacks Consensus Estimate by 1.9%.
BSX has an estimated long-term earnings growth rate of 16.4% compared with the industry’s 13.2% growth. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 7.36%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
CBLL Gets FDA Consent for One-of-a-Kind Delirium Monitoring Solution
Key Takeaways
CeriBell Inc. (CBLL - Free Report) recently announced that the FDA has given 510(k) clearance for its latest delirium monitoring solution, making it the one and only FDA-cleared solution for continuous tracking of delirium. This milestone confirms the Ceribell System as an AI-driven brain-monitoring platform, extending its clinical efficacy by giving doctors useful information to detect risk for both seizures and delirium in more critically ill patients.
Delirium is a major unaddressed critical condition, as current screening relies on occasional bedside assessments, depending on personal judgment, which can vary from one clinician to another. CBLL’s FDA-approved Delirium Monitoring Solution continuously monitors brain activity through electroencephalography (EEG) and notifies clinicians when it sees patterns that suggest delirium. Stanford anesthesiology expert Dr. Juliana Barr says that the technology can potentially improve delirium detection rates, allow faster treatment and reduce the cost burden on both families and hospitals due to missed or delayed diagnoses.
Management noted that the FDA clearance enables CBLL to enlarge its footprint in delirium care by offering the first continuous, objective EEG technology to support doctors with early detection of delirium in critically ill patients. Further, the company will soon wrap up its launch plans and will deliver this breakthrough AI-powered neuro-monitoring technology to patients, making EEG a system-wide standard for brain care.
Likely Trend of CBLL Stock Following the News
Shares of CBLL have lost 3.8% since the announcement on Wednesday. Year to date, shares of CeriBell have declined 21.1% against the industry’s 1.1% growth and the S&P 500’s 19.5% rise.
Image Source: Zacks Investment Research
In the long run, the FDA clearance gives CeriBell a competitive advantage as well as supports its long-term mission of making continuous AI-based EEG technology a standard, essential tool in detecting seizure and delirium — a condition that affects up to 31% of ICU patients, 80% of ventilated patients and increases mortality rate by 10%, with longer hospital stays and higher post-ICU dementia risk. CBLL’s ability to deliver continuous AI-driven monitoring in serious neurological conditions reinforces its strategic vision of making EEG a new vital sign.
CBLL currently has a market capitalization of $748.59 million.
More on the Delirium Monitoring Solution
CBLL’s newly cleared point-of-care EEG system addresses key gaps in delirium, seizure and electrographic status epilepticus care by routine EEG-based screening that provides clinicians with real-time neurological insights to support earlier detection, reduce clinical variability and improve bedside decision-making.
CBLL’s delirium algorithm was tested on 225 critically ill adults, showing real-world reliability. The FDA clearance builds on the technology’s earlier Breakthrough Device Designation and the company has also applied for a New Technology Add-on Payment (NTAP) to the Centers for Medicare and Medicaid Services (CMS) to support hospitals with reimbursement benefits.
Studies show that nearly 48% of ICU patients undergoing seizures develop peri-ictal delirium, and 42% of older ICU patients with delirium show epileptiform discharges. Hence, by innovating an advanced seizure and delirium monitoring tool, CBLL enables thorough diagnosis of patient brain health and guides treatments that may improve outcomes.
CeriBell, Inc. Price
CeriBell, Inc. price | CeriBell, Inc. Quote
CBLL’s Zacks Rank & Key Picks
Currently, CBLL carries a Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space are Phibro Animal Health (PAHC - Free Report) , AtriCure (ATRC - Free Report) and Boston Scientific (BSX - Free Report) .
Phibro Animal Health, sporting a Zacks Rank #1 (Strong Buy) at present, reported third-quarter 2025 adjusted earnings per share (EPS) of 73 cents, which surpassed the Zacks Consensus Estimate by 23.73%. Revenues of $363.9 million beat the Zacks Consensus Estimate by 2.6%. You can see the complete list of today’s Zacks #1 Rank stocks here.
PAHC has an estimated long-term earnings growth rate of 12.8% compared with the industry’s 13.2% rise. The company beat earnings estimates in the trailing four quarters, the average surprise being 20.77%.
AtriCure, currently carrying a Zacks Rank #2 (Buy), reported a third-quarter 2025 adjusted loss per share of 1 cent, narrower than the Zacks Consensus Estimate by 90.91%. Revenues of $134.3 million beat the Zacks Consensus Estimate by 2.09%.
ATRC has an estimated earnings growth rate of 64.2% for 2025 compared with the industry’s 11.5% rise. The company beat earnings estimates in the trailing four quarters, the average surprise being 67.06%.
Boston Scientific, currently carrying a Zacks Rank #2, reported a third-quarter 2025 adjusted EPS of 75 cents, which surpassed the Zacks Consensus Estimate by 5.63%. Revenues of $5.07 billion beat the Zacks Consensus Estimate by 1.9%.
BSX has an estimated long-term earnings growth rate of 16.4% compared with the industry’s 13.2% growth. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 7.36%.